{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide","verification":{"valid":true,"entries":9,"head":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"},"count":9,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12","hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","summary":"RCT evaluating semaglutide in T1D + obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22","hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"verified","prev":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa","hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","summary":"New Phase III trial registration for semaglutide (Jul 2025).","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:15.855Z","link_status":"ok","quote_status":"unverified","prev":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87","hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","summary":"Discusses semaglutide benefits in CV and kidney outcomes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506","hash":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","summary":"Real-world study on semaglutide weight loss, published Jun 2026.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5","hash":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","summary":"Study on weight loss efficacy of semaglutide 2.4 mg.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d","hash":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","summary":"Exploratory analysis from SELECT trial on hospitalizations.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:01:40.686Z","link_status":"ok","quote_status":"unverified","prev":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa","hash":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"}]}